Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
20–55
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Male Japanese subjects who are atopic as determined by an in vitro test (CAP-RAST or MAST test)
Serum IgE level must be equal to or greater than 30 IU/mL at screening.
You may not be if
Poorly controlled asthma i.e. symptoms of asthma (daytime or night-time) or use of short-acting beta agonist for relief of asthma (except with exercise) more than once a week
Worsening of asthma signs and symptoms prompting a medical intervention within 1 year prior to dosing
Severe atopic dermatitis within 1 year prior to dosing, defined by a history of eruption with severe inflammation such as erythema, papule, erosion, infiltration and lichen
Severe allergic rhinitis strongly disturbing daily life within 1 year prior to dosing
Severe allergic conjunctivitis (e.g., episodes of giant papillary, limbal proliferation, shield ulcer) within 1 year prior to dosing
